Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group
Haruyasu Murakami, Takeharu Yamanaka, Takashi Seto, Kenji Sugio, Isamu Okamoto, Toshiyuki Sawa, Tomonori Hirashima, Koji Takeda, Shinji Atagi, Masahiro Fukuoka, Yoichi Nakanishi, Kazuhiko Nakagawa and Nobuyuki Yamamoto
Article first published online: 12 JUL 2014 | DOI: 10.1111/cas.12448
A randomized phase II study was evaluate the efficacy and safety of zoledronic acid in combination with docetaxel in previously treated patients with non-small cell lung cancer (NSCLC) and bone metastases. This study demonstrated the safety and tolerability of the combination of zoledronic acid and docetaxel but did not meet the primary endpoint of PFS in advanced NSCLC patients with bone metastasis.